PHAT
PhathomCNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-06-02
Current thesis
Positive clinical readouts and a non-dilutive partnership would materially de-risk the pipeline and support roughly 2x upside from the anchor, consistent with the bull target.
Posture
Mixed
Lead driver
Sentiment
What changed
Sentiment remains the lead driver in the composite, 7D delta +8.0.
What can break
Clinical failure or the need for dilutive financing would compress value toward ~50% of the anchor, consistent with the bear target and a materially lower recovery valuation.
Momentum
15
Value
41
Sentiment
100
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $15.62 · Bull $31.24 · Bear $7.81
Data freshness
Prices
As of 2026-06-02
Fundamentals
As of 2026-06-01 • Vendor: Data Vendor v1
Scores
As of 2026-06-02 • Model: HYBRID_IC_RP
AI Memo
As of 2025-11-29 • Model: RankAlpha Sentiment AI
Investment thesisAs of 2026-06-02
Investment thesis
As of 2026-06-02
Supporting evidence
What
Grade C · Mixed
Confidence Medium · Net Neutral
Target $23.50
Why
Momentum15 · Δ7d -18.2
Value41 · Δ7d +0.1
Sentiment100 · Δ7d +8.0
So what
Balanced signals (Net Neutral). Wait for confirmation before sizing up.
Lead driver: Sentiment · See AI snapshot
Momentum
15
34% active weight
Current posture
7d trendSoftening
Δ7d
-18.2
Δ21d
-21.1
Value
41
32% active weight
Current posture
7d trendFlat
Δ7d
+0.1
Δ21d
+0.2
Sentiment
100
33% active weight
Current posture
7d trendImproving
Δ7d
+8.0
Δ21d
+24.2
Why this grade
Composite grade C. Momentum 15.2 / Value 41.1 / Sentiment 100.0
Fundamentals (TTM)As of 2026-06-01
Fundamentals (TTM)
As of 2026-06-01
Market Cap
$736.95M
Beta
0.52
Shares Out
71.14M
P/E (TTM) · Derived
-3.4
P/S (TTM)
7.65
P/FCF (TTM) · Derived
-3.32
Rev YoY
+202.7%
EPS YoY
+69.2%
Gross Margin
+87.2%
Op Margin
-145.0%
Net Debt
$257.18M
Current Ratio
2.23
As of 2026-06-02 • Updated nightlySource: Internal modelMethodology